Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06589440 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
A Phase 2 study of Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), sponsored by Stingray Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 6
- Study locations
NCT06589440: Recruiting Phase 2 study of Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), sponsored by Stingray Therapeutics.
NCT06589440 is a Phase 2 study of Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) that is actively recruiting participants, run by Stingray Therapeutics. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06589440, a Phase 2 study of Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), is actively recruiting participants, sponsored by Stingray Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.
Primary Outcome
Part 1 of the study is to establish the recommended dose of SR-8541A in combination with botensilimab and balstilimab.
Conditions Studied
Interventions
- DRUG SR-8541A
Study Locations (6)
Texas
- Texas Oncology- Austin - Austin
- Texas Oncology- Sammons- DFW - Dallas
- The University of Texas M.D. Anderson Cancer Center GI Medical Oncology Dept - Houston
- Texas Oncology- Northeast Texas - Tyler
New Jersey
- Atlantic Health - Morristown
Washington
- Swedish - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06589440 shows while recruiting
NCT06589440 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) appearing as the primary indexed condition, and to 1 intervention - of which SR-8541A is the first listed.
NCT06589440 lists 6 locations in 3 states (Texas, New Jersey, Washington).
Frequently Asked Questions
What is clinical trial NCT06589440 about?
NCT06589440 is a clinical study titled "Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)". This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.
What is the current status of trial NCT06589440?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2024-11-20. Estimated completion is 2027-09.
What conditions does trial NCT06589440 study?
This clinical trial studies the following conditions: Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC).
What interventions are being tested in trial NCT06589440?
The interventions under investigation include: SR-8541A (DRUG).
Who is sponsoring clinical trial NCT06589440?
This trial is sponsored by Stingray Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06589440 being conducted?
This trial has 6 study locations across New Jersey, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06589440's enrollment target sits among peer trials
70 937th of 2000 higher than 1,037 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI